There are currently 31 clinical trials in Tuscaloosa, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Tuscaloosa VA Medical Center, Tuscaloosa, AL, DCH Cancer Treatment Center and University of Alabama. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Tuscaloosa Surgery Center, Tuscaloosa, Alabama
Conditions: Lumbar Spinal Stenosis
Register for Updates
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05813275
Recruiting
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Alabama Neurology & Sleep Medicine, Tuscaloosa, Alabama
Conditions: OSA
Register for Updates
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154
Recruiting
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
04/10/2024
Locations: Research Site, Tuscaloosa, Alabama
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Comparing Two Different Emotion Therapies for Autistic Youth and Young Adults
NCT06158581
Recruiting
Too few clinicians are able and willing to help autistic patients. A recent review identified challenges to mental health service delivery in autism, including a lack of interventions designed for community implementation and limited workforce capacity. It has been argued that improving impairment in emotion regulation has the potential to improve a range of mental health difficulties in autistic people. In this clinical trial, the investigators are comparing two evidence-based interventions for... Read More
Gender:
All
Ages:
Between 12 years and 25 years
Trial Updated:
04/02/2024
Locations: University of Alabama, Tuscaloosa, Alabama
Conditions: Autism Spectrum Disorder
Register for Updates
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
NCT05758415
Recruiting
The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with standard of care, in improving signs, symptoms and physical function in participants with moderate to severe rotator cuff tendinopathy (RCT), using a randomized, double-blind, placebo controlled, parallel group design to minimize bias.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/02/2024
Locations: Clinic for Rheumatic Diseases ., Tuscaloosa, Alabama
Conditions: Rotator Cuff Tendinopathy
Register for Updates
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935
Recruiting
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
03/29/2024
Locations: Gastro Care PC - CAR, Tuscaloosa, Alabama
Conditions: Eosinophilic Esophagitis
Register for Updates
Improving Access and Affordability of Adult Hearing Healthcare
NCT04671381
Recruiting
This project will address quality of care issues associated with hearing loss in adults who have mild-to-moderate hearing loss and who have no access to hearing healthcare. Through the use of three different interventions involving over-the-counter hearing aids, it will lead to options that will increase access and affordability of hearing healthcare for adults with mild-to-moderate hearing loss.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/18/2024
Locations: The University of Alabama, Tuscaloosa, Alabama
Conditions: Hearing Loss
Register for Updates
Spices for Cultivating a Healthy Gut Microbiome and Cardiometabolic Profile
NCT06313580
Recruiting
Among food products receiving attention for prebiotic functionality, spices represent a flavorful vehicle for cultivating a healthy gut microbiota. As the required doses of spice-derived polyphenols to elicit prebiotic and systemic metabolic effects are not well-characterized, additional research is warranted. Thus, the investigators propose to use a food-first synbiotic (prebiotic + probiotic) approach to examine alterations in the gut microbiota pre- and post-intervention/placebo and their rel... Read More
Gender:
Female
Ages:
Between 50 years and 69 years
Trial Updated:
03/18/2024
Locations: The University of Alabama, Tuscaloosa, Alabama
Conditions: Cardiometabolic Syndrome
Register for Updates
Together in Recovery With Veterans Through Employment
NCT05388812
Recruiting
The purpose of this study is to help Veterans who have opioid use problems with gaining and maintaining meaningful employment. The investigators also want to know employment helps with other aspects of the Veteran's life including starting and staying on necessary medications, mental health needs, and feeling a part of society.
Gender:
All
Ages:
19 years and above
Trial Updated:
02/28/2024
Locations: Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama
Conditions: Veterans With Opioid Use Disorder
Register for Updates
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
NCT04375033
Recruiting
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-24 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 3 years a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama
Conditions: Opioid Use Disorder
Register for Updates
The Influence of Aerobic Exercise on Consolidation of Fear Extinction Learning in PTSD
NCT06144203
Recruiting
This study aims to test whether aerobic exercise performed after fear extinction learning improves cognitive, physiological, and neural indices of extinction recall in a sample of trauma-exposed men and women with and without posttraumatic stress disorder (PTSD). Participants will complete a clinical intake visit (Day 0), followed by a three-day fear conditioning (day 1), fear extinction + activity (day 2), and fear extinction recall (day 3) protocol.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
02/13/2024
Locations: Wade Hall - University of Alabama, Tuscaloosa, Alabama
Conditions: PTSD
Register for Updates
Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)
NCT04452500
Recruiting
The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
02/12/2024
Locations: Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama
Conditions: PTSD
Register for Updates